Jakubowiak, A. J., Griffith, K. A., Reece, D. E., Hofmeister, C. C., Lonial, S., Zimmerman, T. M., . . . Richardson, P. G. (2011). Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: A phase 1/2 Multiple Myeloma Research Consortium trial. American Society of Hematology.
Dyfyniad Arddull ChicagoJakubowiak, Andrzej J., et al. Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Phase 1/2 Multiple Myeloma Research Consortium Trial. American Society of Hematology, 2011.
Dyfyniad MLAJakubowiak, Andrzej J., et al. Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Phase 1/2 Multiple Myeloma Research Consortium Trial. American Society of Hematology, 2011.